KontRASt-01: Preliminary Safety and Efficacy of JDQ443+TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

被引：0
|
作者：
Negrao, M. V. [1 ]
Cassier, P. A. [2 ]
Solomon, B. [3 ]
Schuler, M. [4 ]
Rohrberg, K. [5 ]
Cresta, S. [6 ]
Dooms, C. [7 ,8 ]
Tan, D. S. W. [9 ]
Loong, H. H-F. [10 ]
Amatu, A. [11 ]
Assmann, K. Krueger [12 ]
Fairchild, L.
Sansregret, L. [13 ,14 ]
Fan, L.
Farago, A. F. [13 ]
Cho, B. C. [15 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Ctr Leon Berard, Lyon, France
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[5] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] Univ Hosp Gasthuisberg, Leuven, Belgium
[8] Katholieke Univ Leuven, Leuven, Belgium
[9] Natl Canc Ctr Singapore, Duke NUS Med Sch, Singapore, Singapore
[10] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[11] Niguarda Canc Ctr, Grande Osped Metropolitano Niguarda, Milan, Italy
[12] Novartis Inst BioMed Res, E Hanover, NJ USA
[13] Novartis Inst BioMed Res, Cambridge, MA USA
[14] Novartis Inst BioMed Res, Basel, Switzerland
[15] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Solid tumors; KRASG12C inhibitor; Phase I; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA06.03
引用
收藏
页码：S117 / S118
页数：2
相关论文
共 50 条
  • [21] Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
    Rojas, C.
    Lugowska, I.
    Juergens, R.
    Sacher, A.
    Weindler, S.
    Sendur, M. A. N.
    Dziadziuszko, R.
    Pal, A.
    Castanon Alvarez, E.
    Ahern, E. S.
    Lakhani, N.
    Chen, L-C.
    Jemielita, T.
    Choi, Y. S.
    Stathis, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S466 - S467
  • [22] KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
    Sabari, Joshua K.
    Park, Haeseong
    Tolcher, Anthony W.
    Ou, Sai-Hong Ignatius
    Garon, Edward B.
    George, Ben
    Janne, Pasi A.
    Moody, Susan Elizabeth
    Tan, Eugene Y.
    Sen, Suman Kumar
    Peters, Dana
    Yan, Xiaohong
    Christensen, James G.
    Chi, Andrew S.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [23] NURSING EXPERIENCE WITH PATIENTS RECEIVING SOTORASIB FOR KRAS G12C-MUTATED SOLID TUMORS: FOLLOW-UP FROM THE PHASE 1/2 CODEBREAK 100 STUDY
    Dozier, Askia
    Fitzpatrick, Victoria
    Liu, Dazhi
    Hull, Jennifer
    Varrieur, Tracy
    McGuire, Lauren
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : 22 - 23
  • [24] Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial
    He, Yandong
    Huang, Xuhong
    Li, Xiaoxia
    Liu, Hongwei
    Liu, Min
    Tao, Junjia
    Shan, Yuanzhou
    Raza, Hafiz Khuram
    Liu, Yanqiu
    Zhong, Wenting
    Cao, Xue-ping
    Yang, Yuan-yuan
    Li, Ruimei
    Fang, Xian-long
    Zhang, Kang-jian
    Zhang, Rong
    Liu, Feng
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [25] Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
    Skoulidis, Ferdinandos
    Li, Bob T.
    Hochmair, Maximilian
    Govindan, Ramaswamy
    Vincent, Mark
    van der Wekken, Anthonie J.
    Reguart Aransay, Noemi
    O'Byrne, Kenneth J.
    Girard, Nicolas
    Griesinger, Frank
    Nishio, Makoto
    Haefliger, Simon
    Lindsay, Colin
    Reinmuth, Niels
    Paulus, Astrid
    Papakotoulas, Pavlos
    Kim, Sang-We
    Ferreira, Carlos Gil
    Pasello, Giulia
    Duruisseaux, Michael
    Gennatas, Spyridon
    Dimou, Anastasios
    Mehta, Bhakti
    Kormany, William
    Nduka, Chidozie
    Sylvester, Brooke E.
    Ardito-Abraham, Christine
    Wang, Yang
    de Langen, Adrianus Johannes
    ONCOLOGIST, 2025, 30 (01):
  • [26] Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
    Zhao, Jun
    Fang, Jian
    Yu, Yan
    Chu, Qian
    Li, Xiaoyan
    Chen, Jiayan
    Liu, Zhe
    Zhang, Li
    Wu, Lin
    Zhuang, Wu
    Li, XingYa
    Zhao, Yanqiu
    Xing, Ligang
    Liu, Lian
    Bai, Chunmei
    Dong, Xiaorong
    Song, Qibin
    Pan, Pinghua
    Fang, Xuefeng
    Wang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency
    Janne, P. A.
    Spira, A.
    Riely, G. J.
    Gadgeel, S.
    Heist, R.
    Ou, S-H. I.
    Johnson, M. L.
    Sabari, J.
    Velastegui, K.
    Christensen, J. G.
    Yang, W.
    Anderes, K.
    Chao, R.
    Paweletz, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S41 - S42
  • [28] Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
    Wang, J.
    Zhao, J.
    Zhong, J.
    Li, X.
    Fang, J.
    Yu, Y.
    Li, X.
    Fang, X.
    Chang, J.
    Liu, Z.
    Zhao, Y.
    Song, Q.
    Bai, C.
    Wang-Gillam, A.
    Ding, Y.
    Rao, Z.
    Bi, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S459 - S459
  • [29] A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.
    Lindsay, Colin R.
    Veluswamy, Rajwanth
    Castro, Gilberto
    Tan, Daniel Shao-Weng
    Caparica, Rafael
    Glaser, Sabine
    Malhotra, Shweta
    Boran, Aislyn
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] A Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation
    Lindsay, Colin R.
    Tan, Daniel
    Malhotra, Shweta
    Caparica, Rafael
    Boran, Aislyn D.
    Castro, Gilberto
    Glaser, Sabine
    Veluswamy, Rajwanth R.
    Felip, Enriqueta
    CANCER RESEARCH, 2023, 83 (08)
12345